Myra Happe
A5088108000- Viral Infections and Outbreaks Research
- HIV Research and Treatment
- Viral Infections and Vectors
- Malaria Research and Control
- Mosquito-borne diseases and control
- Computational Drug Discovery Methods
- SARS-CoV-2 and COVID-19 Research
- Virus-based gene therapy research
- Hepatitis B Virus Studies
- Research on Leishmaniasis Studies
- Pneumonia and Respiratory Infections
- Global Security and Public Health
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- Influenza Virus Research Studies
- CAR-T cell therapy research
- Bacteriophages and microbial interactions
- vaccines and immunoinformatics approaches
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- Hepatitis Viruses Studies and Epidemiology
- Immunodeficiency and Autoimmune Disorders
- Virology and Viral Diseases
National Institute of Allergy and Infectious Diseases
2022-2025
National Institutes of Health
2022-2024
Peking University
2022
Bipar
2022
Medical University of South Carolina
2019
New approaches for the prevention and elimination of malaria, a leading cause illness death among infants young children globally, are needed.We conducted phase 1 clinical trial to assess safety pharmacokinetics L9LS, next-generation antimalarial monoclonal antibody, its protective efficacy against controlled human malaria infection in healthy adults who had never or received vaccine malaria. The participants L9LS either intravenously subcutaneously at dose mg, 5 20 mg per kilogram body...
Ebola virus disease (EVD) is a filoviral infection caused by species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan (SUDV). We investigated safety immunogenicity heterologous prime-boost regimen involving chimpanzee adenovirus 3 vectored vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed recombinant modified vaccinia Ankara EBOV (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials healthy adults United States (US) Uganda...
Advances in therapeutic drugs have increased life-expectancies for HIV-infected individuals, but the need an effective vaccine remains. We assessed safety and immunogenicity of HIV-1 vaccine, Trimer 4571 (BG505 DS-SOSIP.664) adjuvanted with aluminum hydroxide (alum), HIV-negative adults.We conducted a phase I, randomized, open-label, dose-escalation trial at National Institutes Health Clinical Center Bethesda, MD, USA. Eligible participants were HIV-negative, healthy adults between 18-50...
BACKGROUND. HIV-1–specific broadly neutralizing monoclonal antibodies (bNAbs) have emerged as promising interventions with the potential to effectively treat and prevent HIV-1 infections. We conducted a phase I clinical trial evaluating potent CD4-binding site–specific (CD4bs-specific) bNAbs VRC01LS VRC07-523LS in people (PWH) not receiving antiretroviral therapy (ART).
T-cell immunoglobulin and mucin domain 3 (TIM3) is emerging as a potential target for antibody-based checkpoint blockade. However, the efficacy of TIM3 blockade in combination with other treatment modalities, has not been extensively studied. In current work we combined myxoma virus-based oncolytic virotherapy (OV). Our results demonstrate that virus’s ability to initiate an immense antitumor immune response complements shift tumor microenvironment more proinflammatory state. As result, OV...
Background: Human monoclonal antibodies (mAb) may offer an important new tool to reduce malaria morbidity and mortality. The antimalarial mAb CIS43LS confers high level protection at doses of 20 or 40 mg/kg intravenously (IV) following controlled human infection (CHMI). ability mediate lower by subcutaneous (SC) route is unknown.Methods: Malaria-naïve participants aged 18-50 years received 1 (n = 7), 5 4), 10 3) IV 4) SC. Pharmacokinetic (PK) assessments safety analysis were performed....